Wegovy reviews before and after 1 month: what most people actually notice first

The decision you're really making at the one-month mark

If you're a month in and questioning whether Wegovy is working, you're in good company. A question our prescribers hear regularly is some version of: "I've been on it four weeks and I've lost two kilograms, is that it?" The frustration is understandable. You've committed to treatment, you've navigated the cost, and you want to see the numbers move.

But the one-month point isn't a verdict, it's an early data point. The real decision at month one is whether to stay patient with the process or investigate whether something specific is getting in the way. Those are different problems with different answers. Month one on Wegovy is almost universally spent at 0.25mg, a dose that exists to let your system settle rather than to drive the full therapeutic effect. The titration schedule steps up from there, roughly every four weeks, guided by your prescriber.

The timeline for Wegovy to produce measurable results is typically measured in months rather than weeks. That's not a failure of the medicine, it's how semaglutide works, and it's what the trial evidence reflects. If you want to understand what typical progress looks like at this early stage, our Wegovy before and after one month page walks through what people genuinely experience in those first four weeks. Reviews that show dramatic before-and-after pictures at one month are outliers, not the norm, and the context behind before-and-after photos often tells a different story than the image alone.

What the clinical evidence says about month-one results

The STEP 1 trial (one of the pivotal studies behind Wegovy's UK licence) followed 1,961 adults with obesity for 68 weeks. Average weight loss reached approximately 15% of starting body weight by the end of the study. That figure, cited in the STEP 1 paper published in the New England Journal of Medicine, is not a month-one result. It is an endpoint reached after more than a year of consistent treatment and dose escalation.

What month one tends to deliver instead: a noticeable drop in appetite, less interest in food between meals, and sometimes a few kilograms of early loss, part of which reflects water and reduced caloric intake rather than fat loss specifically. That's still meaningful, because the appetite change is often the thing that makes sustained lower-calorie eating feel manageable for the first time.

NICE's appraisal of semaglutide for weight management, TA875, recommends that treatment is reviewed at six months on maintenance dose: if less than 5% of starting body weight has been lost by then, continuing treatment is reconsidered. Six months, not one. One month is the warm-up.

For a broader look at how results accumulate across the treatment period, the Wegovy results and reviews page covers what the evidence shows at different timepoints.

Side effects in the first month, and what's normal versus worth flagging

The most common experiences in month one are gastrointestinal: nausea, loose stools, reduced appetite, and occasionally vomiting or constipation. These are well-documented in the clinical data and tend to be most pronounced in the first one to two weeks after starting or after a dose increase. For many people they ease considerably once the body adjusts.

That said, not everything should be waited out. Seek urgent medical attention for severe, persistent stomach pain (especially pain that extends to the back) which can signal a rare but serious issue with the pancreas. The NHS medicines page for semaglutide sets out the full list of symptoms that need prompt attention, and it's worth reading before you start rather than after something feels wrong.

If side effects in month one are making it difficult to eat adequately or are significantly affecting daily life, that's a conversation to have with your prescriber rather than something to push through alone. Dose timing and dietary adjustments can make a real difference. Reactions worth reporting to the MHRA can be submitted at Yellow Card.

For context on what people report at two months compared to one, the two-month results and before-and-after page covers how the picture typically changes once titration progresses.

What this means for your next step

Reading reviews before and after one month of Wegovy can set expectations in either direction, too high, or not high enough. The useful frame is this: month one is about tolerability and the early appetite signal. If both are present, the medicine is doing its initial job. The weight loss comes as doses increase and time accumulates.

Cost is a real consideration too. Treatment for obesity is a long-term commitment, and it's worth understanding what a full month's supply includes and what different providers charge for the service around it, the weight-loss treatment overview covers how private treatment works in practice.

If you're trying to work out whether Wegovy is right for your situation specifically, that's exactly what a clinical consultation is for. Speak to our prescribers through a free consultation, a GPhC-registered Independent Prescriber reviews your answers the same day, not a bot, and not a queue.